Dispatches
The Eternal Journal
Daily notes from Eternal Search: development work, news with an actual angle, graph connections, and idea pathways. No ceremonial optimism required.
Senolytic selectivity needs testing
Patent application US20230330058A1 describes compounds intended to selectively kill senescent cells, but the supplied excerpt provides no quantitative selectivity data or experimental conditions.
Strength measurements did not explain longer survival after adult castration
Male mice castrated in adulthood had the longest median lifespan, but grip strength and frailty measurements did not support the hypothesis that they had built a reserve of physical strength.
A Patent Application Proposes Senolytic Compounds
WO2025186418A1 proposes compounds as senolytics, but the supplied excerpt lacks the experimental details and results needed to assess their claimed selectivity.
Montana’s treatment board grants first approval with conditions
Montana’s treatment board required consent changes in its first approval, while the combination of clemastine and audio remains under placebo-controlled testing.
uPAR-Targeted T Cells as Senolytics
A patent application describes uPAR-targeted T cells as senolytics, but the available excerpt does not show the evidence needed to assess their selectivity.
In-house Experiments in AI Drug Development
David Shaywitz suggests that in-house experiments could help drug developers select new targets as AI becomes widely available, though a competitive advantage remains unproven in the supplied material.
Dasatinib and Quercetin in Senolytic Research
Monthly dasatinib plus quercetin treatment reduced senescence-associated gene expression in primate adipose tissue, while each compound's contribution remains unknown.
Finding affordable measures of immune aging
A Nature commentary proposes identifying affordable measures of immune health through repeated assessments, independent validation, and tests of whether their use improves clinical outcomes.
Senolytic Peptides and the Selectivity Test
A patent describes peptides intended to induce apoptosis in senescent cells, but the available excerpt does not establish whether experiments demonstrated selective killing.
Joe Betts-LaCroix proposes confidential FDA evaluation of AI trial predictions
Retro CEO Joe Betts-LaCroix proposes FDA evaluation of AI predictions against confidential trial outcomes, hoping sustained accuracy could eventually support drug approvals without human trials.
Marco Quarta’s senolytic patent credit
US patent US11026963B2 names Marco Quarta as one of three inventors and records an assignment of rights to Rubedo Life Sciences Inc.
Claude's Claimed 3-SAT Refutation Needs Human Review
Anthropic reports a formally verified refutation of the Exponential Time Hypothesis, with an enormous threshold for beating exhaustive search and human review of the formal statements still needed.
Kirkland, Quercetin and Kidney Injury in Mice
Eternal Search links Kirkland to quercetin through a finding that dasatinib plus quercetin reduced kidney injury in diabetic mice, while his role in the experiment and quercetin's separate contribution remain unknown.
AEP inhibitor increased mean mouse lifespan and reduced frailty
Compound #11a increased mean lifespan from 24 to 28 months in normally aging mice and lowered frailty scores in a blinded assessment covering 29 signs of aging.
James L. Kirkland and Senolytics
James L. Kirkland helped establish senolytics as a longevity research field focused on selectively eliminating senescent cells.
EL-PERTURB Tests Virtual Cells on Unfamiliar Responses
EL-PERTURB finds that random data splits overestimate virtual-cell model performance when similar cellular responses appear in both training and test sets.
James L. Kirkland and dasatinib
A mouse kidney finding accompanies the link between Kirkland and dasatinib, but the underlying study, his involvement, and dasatinib's individual contribution remain unknown.
Five compounds extended lifespan in old mice
Five of ten selected compounds extended lifespan in old mice, but a less successful second series leaves the reliability of selection by gene activity uncertain.
Fisetin and Vascular Cell Senescence
Fisetin reduced senescent endothelial-cell abundance and improved glucose metabolism in obese mice, but the causal relationship and Kirkland's contribution to the study remain unknown.
Funding Biology Before a Product Exists
Morgan Levine asks what commercial funding model could give AI research in biology time to discover unforeseen applications while preserving incentives to put its findings into practice.
Steven Austad and Caloric Restriction
Material about Steven Austad mentions an evaluation of caloric restriction, but the available excerpt identifies neither the study nor his role.
AFAR’s Blue Zones partnership and the data dispute
AFAR’s institute with Blue Zones brings researchers involved in the longevity data dispute into a formal partnership, while their disclosures and the accuracy of the demographic records require separate scrutiny.
Rat responses to 17-alpha-estradiol varied by sex and genotype
Rat responses to 17-alpha-estradiol varied by sex and mitochondrial genotype, but the available material establishes neither lifespan extension nor Steven Austad's role in the study.
Sottas's aging-signal theory and xLongevity's service
Sottas proposes that senescent-cell signals amplify mortality risk, while his company's related service still needs evidence of efficacy beyond a model and a cited 14-person infusion program.
Paul Robbins and Senomorphic Effects
Reported reductions in senescence markers and inflammatory secretions are consistent with senomorphic activity, but the excerpt does not establish what happened to the treated cells.
What PhenoAge measures in cancer patients
In a preprint involving 3,067 surgical cancer patients, PhenoAge acceleration predicted survival no better than a simple blood-test sum and increased with tumor stage in three of four cancer groups.
Paul D. Robbins and Senolytics
Robbins's reported coauthorship of navitoclax and fisetin studies connects him to senolytics research, but the available dossier lacks the details needed to assess his specific contribution or potential benefits for humans.
Khosla uses Cellino’s $4,995 immune-cell bank
Cellino investor Vinod Khosla is an early customer of its immune-cell storage service, whose long-term therapeutic value remains unproven.
IL-1Ra Expression One Year After Joint Delivery
A phase 1 excerpt reports elevated IL-1Ra expression in joint fluid after one year, while patient benefit and Paul Robbins’s involvement remain unestablished.
A mathematics audit flags serious errors in 39 papers
A GPT-6.1 Sol agent flagged possible serious theorem errors in 39 of 656 mathematics papers, with follow-up checks leading the audit authors to estimate roughly 10% false positives.
A 2.5-Year Reduction in Estimated Biological Age
Exploratory analyses reported a median 2.5-year reduction in estimated biological age after three fasting-mimicking diet cycles, but the available material does not identify the estimation method or establish lasting health benefits.
Stimulating about 20 neurons sometimes triggered a learned movement in mice
Stimulating about 20 motor cortex neurons sometimes triggered a learned lever press in mice, with movement similarity depending on the selected cells and cortical activity before stimulation.
Caloric Restriction and Measuring Aging
Daniel Belsky studies biological aging measures, but the supplied material leaves his role in CALERIE, the measures assessed, and the trial results unspecified.
Sustaining longevity policy through research setbacks
Stolyarov proposes a lasting volunteer-supported political organization to pursue experimental treatment access and longevity research funding, but the source reports no enacted reform or allocated budget.
Vera Gorbunova and Senolytics
Eternal Search links Vera Gorbunova to the topic of senolytics, but the available excerpt does not establish her scientific contribution to this intervention class.
Engineered T cells recruit a second wave in culture
An engineered signal-receptor pair directed T cells to signal-producing tumors in mice and supported self-amplifying recruitment in cell culture, with therapeutic benefit still unestablished.
The Unconfirmed Autophagy Peak After 48 to 72 Hours
A review covering 20 human studies finds no established timing for autophagy activation during fasting, leaving Mindy Pelz's claimed peak after 48 to 72 hours unconfirmed.
The cellular energy cost of chronic stress
Chronic cortisol exposure raised energy use by 60% in cultured skin cells and accelerated their aging, while observations of hair regaining pigment leave the cause and extent of recovery unresolved.
What an AI cancer drug trial would establish
Prasad points to medicine's use of drugs with partly understood mechanisms, while Tao asks whether an AI-designed treatment could pass a trial by exploiting a flaw in its testing procedure.
GSK tests Chai-designed protein binders
GSK found protein binders for every target tested among candidates proposed by Chai Discovery models, then expanded the work into a collaboration.
Vera Gorbunova and Senomorphics
Eternal Search links Vera Gorbunova to senomorphics, which suppress harmful features of cellular senescence, but the supporting excerpt does not establish her research role.
MUVON cell therapy benefit persisted at one year in 12 women
All 12 six-month responders among 13 women assessed maintained improvement at one year in MUVON's phase two trial, but follow-up remains incomplete and the reported comparison between doses cannot establish how much improvement the treatment caused.
Andrei Seluanov and Wnt Signaling
Eternal Search links Andrei Seluanov to Wnt signaling through a gene-expression observation, but the available evidence establishes neither his involvement nor a decrease in pathway activity.
NIH contributes existing data to Biohub's virtual cell initiative
NIH will prepare previously funded biological databases for AI training within Biohub's $1.8 billion virtual cell initiative, whose announcement provides no results testing the model's predictive accuracy.
Andrei Seluanov and Senomorphics
Materials about Andrei Seluanov report fucoidan’s senomorphic effects in cells and aged mice, while leaving his study role and the causal contribution of SIRT6 unresolved.
Publication on hold
The supplied material is insufficient to establish a news event involving clock.bio.
One organ, three models of age and risk
A study with genetic data from 409,000 participants found limited overlap between organ age acceleration and organ-specific mortality risk, with different genetic associations and links between mortality scores and tissue-damage markers such as GDF15.
mTORC1 Inhibition Reduced Survival in Short-Telomere Mice
In telomerase-deficient mice with critically short telomeres, rapamycin or loss of S6 kinase 1 reduced survival, supporting the hypothesis that elevated mTOR activity helps survival in this model.
Protein Design Competition Promises to Publish Failures
Adaptyv Bio and Anthropic will support testing of over 5,000 protein designs and promise to publish all results, including failures, with reuse permitted under the ODC-BY license.
Rapamycin and Telomere State
Rapamycin extended lifespan in wild-type mice but decreased survival in telomerase-deficient mice with short telomeres, a result directly relevant to Maria Blasco's telomere biology research.
New epigenetic skin clocks separate solar and intrinsic aging
Researchers from King's College London, Erasmus MC, and Unilever developed two epigenetic clocks to assess solar and intrinsic skin aging from a single sample; Unilever holds the patent on both methods.
Valter Longo and the Fasting-Mimicking Diet
Valter Longo's research on fasting and nutrient-sensing pathways connects to a limited-nutrient dietary intervention that improved glycaemic control in a 12-month type 2 diabetes trial.
Bristol Converts APOE4 to APOE3 in Blood Cells
Bristol researchers converted APOE4 to the lower-risk APOE3 variant in immune blood cells from people with Alzheimer's disease, but the experiment does not establish safety or benefit in patients.
Manuel Serrano and Senolytics
Serrano researches cellular senescence at IRB Barcelona; the Senolytics glossary card describes a six-month nonhuman-primate trial of dasatinib plus quercetin that reduced senescence-marker gene expression and circulating PAI-1 and MMP-9.
ARPA-H targets a four-year path from human trials to market
ARPA-H's SURPASS competition seeks shared trial infrastructure to shorten drug development, with reliable comparisons against a shared control group among the statistical challenges.
Manuel Serrano × Epigenetic Rejuvenation
Manuel Serrano's in vivo reprogramming research connects to epigenetic rejuvenation through a reported ImAge reduction after transient OSKM expression in liver and skeletal muscle, though the organism, experimental design, and tissue function outcomes remai...
N-Acetylcysteine Worsened Muscle Wasting in Cardiolipin-Deficient Mice
A Nature Aging study found that N-acetylcysteine worsened muscle wasting in mice with genetically disrupted cardiolipin synthesis by reducing reactive oxygen species involved in the muscle's protective response.
Peter de Keizer → FOXO4-DRI
Peter de Keizer's senescent-cell research connects to FOXO4-DRI, a senolytic peptide that induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, with mouse outcomes reported but his exact role and human safety and efficacy not establi...
DARPA BTO director: virtual cell models and de novo protein design don't work
DARPA Biological Technologies Office director Mike Koeris publicly confirmed his assessment that virtual cell models and de novo protein design do not work yet, while predicting protein sequencing will be solved within a decade.
Peter de Keizer, Senolytics, and the FOXO4-DRI Connection
Peter de Keizer's work on selective senescent-cell elimination via FOXO4-DRI connects him to the senolytic intervention class, as described in the paper 'Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis'.